Anlotinib-based Combination Therapy in Patients with Hormone Receptor-positive（HR+） Metastatic Breast Cancer(MBC) .

NCT06734533 · clinicaltrials.gov ↗

RECRUITING

Status

80

Enrollment

OTHER

Sponsor class

Conditions

HR+ Breast Cancer

Interventions

OTHER: Anlotinib+eribulin/nab-paclitaxel/etoposide/capecitabine/pembrolizumab/ sintilimab/ fulvestrant, etc

Sponsor

Hunan Cancer Hospital